Amyloid- Monoclonal Antibody
| Catalog number: | B2019648 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 100 uL |
| Molecular Weight or Concentration: | NA |
| Supplied as: | Liquid |
| Applications: | a molecular tool for various biochemical applications |
| Storage: | -20C |
| Keywords: | Anti-ABCC12 Antibody |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Selkoe, D. J. (1994). The cell biology of beta-amyloid precursor protein and presenilin in Alzheimers disease. *Journal of Cell Science*, 107(5), 1097-1102.
- Hardy, J., & Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimers disease: progress and problems on the road to therapeutics. *Science*, 297(5580), 353-356.
- Haass, C., & Selkoe, D. J. (1993). Soluble protein oligomers in neurodegeneration: lessons from the Alzheimers amyloid beta-peptide. *Nature*, 373(6513), 510-512.
- Karran, E., & Walker, L. (2013). The amyloid cascade hypothesis: are we poised for success? *Nature Reviews Drug Discovery*, 12(10), 751-752.
- De Strooper, B., & Karran, E. (2016). The cellular phase of Alzheimers disease. *Cell*, 164(4), 603-615.
- Selkoe, D. J. (2001). Alzheimers disease: genes, proteins, and therapy. *Physiological Reviews*, 81(2), 741-766.
- Zlokovic, B. V. (2004). Neurovascular mechanisms of Alzheimers neurodegeneration. *Nature Reviews Neuroscience*, 5(5), 347-360.
- Iwatsubo, T., et al. (1996). Visualization of A 42(43) and A 40 in Alzheimers disease. *Nature*, 379(6560), 636-639.
- Haeberlein, S. M., et al. (2019). The role of amyloid beta in Alzheimers disease: a review. *Nature Reviews Neuroscience*, 20(5), 299-310.
- Cummings, J. L., et al. (2016). Alzheimers disease drug development pipeline: 2016. *Alzheimers & Dementia*, 12(3), 272-283.
